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ABSTRACT
Background and aims: This prospective trial was
designed to compare the performance characteristics of
five different screening tests in parallel for the detection
of advanced colonic neoplasia: CT colonography (CTC),
colonoscopy (OC), flexible sigmoidoscopy (FS), faecal
immunochemical stool testing (FIT) and faecal occult
blood testing (FOBT).
Methods: Average risk adults provided stool specimens
for FOBT and FIT, and underwent same-day low-dose 64-
multidetector row CTC and OC using segmentally
unblinded OC as the standard of reference. Sensitivities
and specificities were calculated for each single test, and
for combinations of FS and stool tests. CTC radiation
exposure was measured, and patient comfort levels and
preferences were assessed by questionnaire.
Results: 221 adenomas were detected in 307 subjects
who completed CTC (mean radiation dose, 4.5 mSv) and
OC; 269 patients provided stool samples for both FOBT
and FIT. Sensitivities of OC, CTC, FS, FIT and FOBT for
advanced colonic neoplasia were 100% (95% CI 88.4% to
100%), 96.7% (82.8% to 99.9%), 83.3% (95% CI 65.3% to
94.4%), 32% (95% CI 14.9% to 53.5) and 20% (95% CI
6.8% to 40.7%), respectively. Combination of FS with
FOBT or FIT led to no relevant increase in sensitivity. 12 of
45 advanced adenomas were smaller than 10 mm. 46%
of patients preferred CTC and 37% preferred OC
(p,0.001).
Conclusions: High-resolution and low-dose CTC is
feasible for colorectal cancer screening and reaches
sensitivities comparable with OC for polyps .5 mm. For
patients who refuse full bowel preparation and OC or CTC,
FS should be preferred over stool tests. However, in cases
where stool tests are performed, FIT should be
recommended rather than FOBT.
Colorectal cancer is one of the major public health
issues in industrialised countries. Most colorectal
cancers are thought to originate from benign
adenomatous polyps that develop over a period of
many years.1 Early detection followed by removal
of adenomas has been shown to reduce incidence
and colorectal cancer-related mortality.2 3
Therefore, screening of the asymptomatic and
average risk population is recommended by many
organisations and expert panels, and is reimbursed
by insurance companies in several countries.4–7
Next to colonoscopy, flexible sigmoidoscopy (FS)
and guaiac-based faecal occult blood test (FOBT)
are widely applied screening procedures which
have been compared prospectively with each other.
Colonoscopy has been found to be the screening
test with the highest sensitivity and outperforms
FS and FOBT which miss a significant number of
relevant adenomas.8 Colonoscopy, however, is not
a perfect test in itself, and misses 6–12% of large
adenomas.9–11
CT colonography (CTC), also known as virtual
colonoscopy, and faecal immunochemical tests
(FITs) have been proposed as screening tests for
colonic neoplasia.12–14 They have at present not
been integrated into screening programmes. Based
on recent research, CTC shows heterogeneous
results in the detection of colonic polyps: some
studies demonstrated high sensitivity in the detec-
tion of relevant colorectal adenomas,8 13 15 16 while
other trials showed less encouraging results with
reported sensitivities of slightly more than 50%.17 18
Another important issue of CTC is the theoretical
cancer risk associated with the radiation expo-
sure.12 19 Therefore, if this test were to be accep-
table as a mass screening instrument, radiation
exposure of a single examination must be kept low,
repeated examinations need to be avoided and
sensitivity for relevant lesions must be high.
Standard CTC will result in radiation doses of
10–12 mSv. Smaller series operating 4-slice scan-
ners with low-dose protocols have reported effec-
tive doses of 2.1–7.8 mSv.15 20 With 64-
multidetector row CTC, increases in dose have
been observed in different anatomical regions.21
Recently, a protocol that employs an online dose
modulation algorithm that will lead to a 35%
decrease in radiation exposure at preserved image
quality was developed.22
Advanced colonic neoplasia comprises the enti-
ties invasive cancer and advanced adenoma.
Advanced adenoma is defined as a lesion of
adenomatous histology that meets at least one of
the following criteria: a size of >10 mm, the
presence of a villous component of at least 25% or
the presence of high-grade dysplasia.23 As these
benign lesion are associated with a relatively high
risk of progression to cancer, their removal
effectively disrupts the adenoma–carcinoma path-
way that is believed to be responsible for the
majority of colorectal cancers.2 24 The prevalence of
advanced adenoma in a screening population lies
Colonic cancer
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within a range of 3.7–15% and the prevalence of cancer has been
reported to be 0.9% (range 0.5–1.3%).8 23 25 While it is not
debated that adenoma larger than 1 cm and cancer need to be
detected by a screening test, the relevance and handling of
diminutive ((5 mm) and small (6–9 mm) adenomas detected
by CTC screening is currently under discussion. Recently,
surveillance of polyps of 6–9 mm in diameter and non-reporting
of diminutive lesions has been advocated.8 13 26 Up to now, there
are no data to support that this strategy would lead to an
increase in carcinoma incidence in a screening population.
However, the prevalence of advanced adenoma in small lesions
is about 5%, and the prevalence of cancer in this size group has
been reported to be 0.1%.27 28
We undertook this study to compare prospectively the
performance of the three most commonly applied colorectal
cancer screening tests, optical colonoscopy (OC), FS and FOBT,
with high-resolution, low-dose CTC and FIT. For the first time,
five different screening tests were compared in the same
patients. CTC examinations were exclusively carried out using
a 64-dector row scanner employing a low-dose protocol. We
report the sensitivity, specificity, and positive and negative
predictive values for the detection of patients with advanced
adenoma and adenoma of various sizes for each test. We
analysed the performance according to the polyp of high-
resolution CTC as a screening instrument compared with OC.
METHODS
Study subjects
The study protocol of this prospective colorectal cancer screen-
ing cohort study was approved by the institutional ethical
committee, and the study meets all criteria put forth by the
Declaration of Helsinki. Participants had to be .50 years of age
and free of symptoms of colonic diseases such as melaenic
stools, haematochezia, diarrhoea, relevant changes in stool
frequency or abdominal pain. Exclusion criteria also included
prior OC within the last 5 years, and positive family history for
colorectal cancer (one first-degree relative diagnosed with CRC
before age 60 or two first-degree relatives diagnosed with CRC
at any age). Persons with a history of or present inflammatory
bowel disease, hereditary colorectal cancer syndromes, a body
weight .150 kg or severe cardiovascular or pulmonary disease
were also excluded. All participants provided written informed
consent before their participation in the trial.
Study procedure
For each enrolled patient, a detailed medical history was taken
prior to CTC. Patients also completed a questionnaire regarding
their personal and family medical history. Patient comfort levels
were assessed before and after CTC as well as after OC using
standardised questionnaires. Study participants were asked to
rate the discomfort related to bowel preparation, CTC and OC
on a 6-point scale. Complaints were rated as 1 = none, 2 = very
mild, 3 = mild, 4 = moderate, 5 = severe, and 6 = unbearable.
Bowel preparation
A package including instructions and medication for bowel
purgation, three FOBT slides and two 10 ml stool sample
containers for FIT was mailed to the participants. Before
initiation of bowel lavage, FOBT samples were taken on three
consecutive days. The two stool samples for FIT were collected
from two different parts from the same stool and stored
refrigerated. Bowel preparation was based on a standard ‘‘wet
prep’’ regimen including 4 litres of polyethylene glycol solution
(KleanPrep, Norgine Pharmaceuticals, Marburg, Germany) and
a commercially available combination of four tablets (5 mg
each, for a total of 20 mg) of bisacodyl and 30 ml of sodium
phosphate (Prepacol, Guerbet Pharma, Sulzbach, Germany).
Study participants were asked to follow a clear liquid diet from
12:00 h the day before the examinations and ingest the
bisacodyl tablets as well as the sodium phosphate solution at
14:00 h, and drink 3 litres of polyethylene glycol (PEG) between
17:00 h and 20:000 h on the day before CTC/OC. The last litre
of PEG was drunk in the morning before examinations. To this
last litre of PEG, 50 ml of the iodinated contrast agent
iopamidol (Solutrast 300, BraccoAltana Pharma, Milan, Italy)
were added in order to tag residual fluid.
CT colonography
CTC scans were performed on a 64-channel multidetector row
scanner (Siemens Somatom Sensation 64, Siemens Medical
Solutions, Forchheim, Germany) at a collimation of 0.6 mm for
high-resolution scanning. Images were reconstructed using a
standard soft tissue kernel at a slice thickness of 0.75 mm and
0.5 mm reconstruction increment. Tube voltage was 120 kVp,
and tube current–time product reference values were 70 mAs in
the supine and 30 mAs in the prone position. An online dose
modulation technique (Care Dose 4D, Siemens Medical
Solutions) was used to adapt the tube current automatically
to patient anatomy,22 and dose–length products were recorded
for calculation of radiation exposure. Effective patient doses
were calculated using appropriately normalised coefficients.29
No intravenous contrast agent was administered. A 20 mg
aliquot of n-butyl scopolamine (Buscopan, Boeringer Ingelheim
Pharmaceuticals, Ingelheim, Germany) was administered intra-
venously for bowel relaxation.
Patients were positioned on the scanner table in the right
decubitus position and bowel distension was achieved after
placement of a rectal tube by manual air insufflation (n = 80) or
automated CO2 application (n = 227) using a commercially
available insufflator (Protocol, E-Z-EM, Lake Success, New
York, USA). Adequacy of colonic distension was determined by
a radiologist on the CT scout film of the abdomen.
Subsequently, the first set of images was obtained in a 7–9 s
breath-hold with the patient in the supine position. After
repositioning, the prone data set was obtained. Data sets were
automatically sent to a 3D workstation (Syngo Workplace 2006
version VB 30, Siemens Medical Solutions). All scans were read
by one of three experienced abdominal radiologists who had
read.300 CTC examinations prior to the study using a primary
3D approach with 2D for problem solving. Immediately after
CTC, patients were transferred to the endoscopy suite.
Optical colonoscopy and flexible sigmoidoscopy
Video colonoscopy was performed by one of six experienced
gastroenterologists who had performed .1000 colonoscopies
each before the start of the trial using video endoscopy (CF-Q
160 series, Olympus Medical Systems, Hamburg, Germany). If
desired, Disoprivan (Propofol, B. Braun Melsungen AG,
Germany) was administered intravenously. Lesions were
measured by comparison of their size with an open biopsy
forceps. All polyps were resected or biopsied and retrieved at
colonoscopy, and sent to histopathology for analysis.
Sigmoidoscopy was defined as endoscopic examination of the
rectum and sigmoid colon. FS results were deduced from OC
results; no separate endoscopy was performed.
Colonic cancer
242 Gut 2009;58:241–248. doi:10.1136/gut.2008.156448
 group.bmj.com on July 8, 2013 - Published by gut.bmj.comDownloaded from 
Documentation and matching of findings
All findings were documented on a standardised report form.
For each of six colonic segments (caecum, ascending colon,
transverse colon, descending colon, sigmoid colon and rectum),
the absence or presence of polyps was determined and lesion
sizes were coded as diminutive ((5 mm), small (6–9 mm) or
large (>10 mm). These size categories were based on previous
research and the consensus statements of the European Society
of Gastrointestinal and Abdominal Radiology and the Working
Group on Virtual Colonoscopy.26 30 In the endoscopy suite, the
report form containing the CTC results was provided to one of
the endoscopy nurses who revealed the results to the
endoscopist after withdrawal of the endoscope from each
colonic segment. This technique, known as ‘‘segmental
unblinding’’, allows for exact correlation of CTC and OC
findings and can therefore be considered an enhanced gold
standard. In the case of a discrepancy between CTC and OC
first-look findings, an immediate colonscopic re-examination
(‘‘second look’’) of the respective colonic segment has to be
performed;13 17 if results were discrepant after the second look,
the radiologist was contacted and described the exact localisa-
tion of the lesion to the endoscopist who subsequently re-
examined the segment. First- and second-look detections at OC
were documented separately. In the case of concordance of CTC
and OC findings, no second-look examination was performed. A
lesion was rated a true positive detection if colonoscopy and
CTC detected a polyp in the same or adjacent segment of the
colon, and if the measured size of the lesion was within the
same size category or if there was a deviation of no more than
one size category.13 Only polyps detected in the rectum and
sigmoid colon were included for analysis of the performance of
flexible sigmoidoscopy.4
Stool tests
FOBTs were performed immediately, and stool samples were
deep frozen at 280uC. The FOBT was judged to be positive if
one of the three samples per patient yielded a positive test
reaction.
For FIT, the provided stool samples were extracted by means
of a stool sampling device (Sentinel Diagnostics, Milan, Italy)
shaped like a standard analyser test tube filled with haemoglo-
bin (Hb) extracting buffer solution. The sample probe of the
device has a serrated tip, which was poked into the stool at
three different positions and pushed back into the tube through
a tight membrane, removing most of the excess stool, leaving a
quantitative amount of 10 mg of stool in the serrations. Test
reproducibility of quantitative stool transfer was shown to be
6.1% at a Hb mean concentration of 198 ng/ml and 5.2% at a
Hb mean concentration of 600 ng/ml (homogenised stool
sample, 11 different positions, two replicates each). After
30 min of mixing on a head-over-head rotator, the sampling
device was de-capped, transferred onto an Architect c8000
Clinical Chemistry Analyzer (Abbott Diagnostics, Abbott Park,
Illinois, USA) and Hb concentration measured by means of the
FOB Gold immunoturbitrimetric latex assay (Sentinel
Diagnostics, Milan, Italy). The FOB Gold assay is based on
the antigen–antibody agglutination between human Hb in the
sample and polyclonal anti-human Hb antibodies absorbed on
polystyrene particles. Agglutination is measured as an increase
in absorbance at 570 nm compared with a standard calibration
curve and is proportional to the concentration of human Hb in
the sample. Between-run confidence values were 5.6% at a Hb
mean concentration of 80.3 ng/ml and 4.6% at a Hb mean
concentration of 304 ng/ml, respectively. The FIT was per-
formed in each of the two samples per patient, and the higher
value among these two entered the calculation. The lowest
detection limit was 14 ng/ml, which corresponds to the cut-off
value for the calculations for specificity and sensitivity.
Statistical analysis
Prior to commencement of the trial, we performed statistical
analyses to determine the required population size. These were
based on the expected prevalence of colonic adenomas in an
asymptomatic European population. Our statistician deter-
mined the number of individuals to be screened by precision
of the 95% CI using normal approximations of binomial
distributions. The study was powered to detect a 10% difference
in OC and CTC sensitivity for detection of polyps .5 mm, and
the number of patients to be screened was determined to be
300. All data were entered into a database and calculations were
done using SAS Statistical Software Version 9.1 (SAS Institute
Inc., Cary, North Carolina, USA). Sensitivities and specificities
were calculated for OC and CTC on a per-polyp basis for
advanced adenomas and for any polyp histology at cut-off sizes
of 5 and 9 mm. Per-patient sensitivities and specificities were
calculated for all tests at size thresholds of 5 and 9 mm.
Specificities, and positive and negative predictive values were
calculated for all tests.
RESULTS
A total of 311 consecutively enrolled asymptomatic adults
underwent same-day CTC and OC (171 men and 140 women,
50–81 years of age, mean (SD) 60.5 (7.0) years). Four persons
had to be excluded because of withdrawal from the trial after
CTC (n = 2) or incomplete colonoscopy (n = 2). Stool samples
for FIT were available in 285 persons, and FOBT slides were
available in 276. Based on an interview prior to inclusion, all
patients were considered to be at average risk. There were no
clinically relevant complications due to OC or CTC. A total of
Table 1 Distribution of adenomas and non-adenomatous polyps in 307
asymptomatic adults
Polyp size
,6 mm 6–9 mm .9 mm All
Rectum
Adenomatous 5 4 5 14
Non-adenomatous 84 6 1 91
Sigmoid colon
Adenomatous 33 16 15 64
Non-adenomatous 78 1 0 79
Descending colon
Adenomatous 24 6 4 34
Non-adenomatous 26 2 0 28
Transverse colon
Adenomatous 22 4 4 30
Non-adenomatous 36 3 1 40
Ascending colon
Adenomatous 41 9 2 52
Non-adenomatous 23 2 1 26
Caecum
Adenomatous 22 2 3 27
Non-adenomatous 24 1 1 26
All segments
Adenomatous 147 41 33 221
Non-adenomatous 271 15 4 290
Colonic cancer
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168 persons (54.7%) chose sedation for colonoscopy. Mean
radiation dose for CTC was 4.5 (0.6) mSv (range 3.5–6.1 mSv).
The supine scan at a reference 70 mAs contributed a mean of
3.2 mSv, and the prone scan a mean of 1.3 mSv.
Table 1 summarises the distribution of polyps according to
size and location. A total of 1842 colonic segments were
analysed in 307 patients. Based on the gold standard (segmen-
tally unblinded OC), 511 lesions were detected, 221 (43.2%)
were adenomatous and 290 (56.8%) non-adenomatous. At least
one adenoma of any size was detected in 113 participants
(36.8%). The maximum number of polyps detected in one
participant was nine. A total of 418 (81.8%) polyps were
(5 mm, 56 (11.0%) polyps measured 6–9 mm, and 37 (7.2%)
polyps were .9 mm. A total of 248 polyps (48.6%; 78
adenomatous and 170 non-adenomatous polyps) were located
within the reach of FS. Forty-six advanced lesions were
detected: 7 lesions measuring (5 mm, 6 lesions measuring 6–
9 mm, and 33 lesions measuring at least 10 mm, including one
stage T3 carcinoma of the transverse colon. The characteristics
of patients with advanced adenoma are shown in table 2.
Table 3 summarises the performance characteristics of the
different methods for detection of adenomas according to the
patient. OC reached the highest sensitivities for patients with
adenomas of all size categories and identified 97.3% of patients
with adenoma of all sizes, 97.8% of patients with adenomas
>6 mm and all patients with adenomas >10 mm. With
sensitivities for identifying patients with adenomas >6 mm
and >10 mm of 91.3% and 92%, respectively, CTC reflected the
excellent performance data reported recently.8 13 An example of
a sessile lesion of.10 mm in size seen at CTC and OC is shown
Table 2 Characteristics of patients with advanced colonic neoplasia
Patient no. Lesion no Sex Age Site Size (mm) Histology Dysplasia OC CTC FS FIT FOBT
1 M 61 Sigmoid colon 14 Villous Low + + + 28 +
2 F 73 Ascending colon 22 Villous Low + + 2 ,14 2
3 M 66 Sigmoid colon 13 Villous Low + + + ,14 2
Transverse colon 5 Villous Low + + 2
Caecum 4 Villous Low + + 2
4 M 68 Caecum 16 Tubular Low + + 2 ,14 2
5 M 73 Sigmoid colon 10 Villous Low + + + 61 +
Rectum 7 Villous Low + + +
6 M 67 Rectum 12 Villous Low + + + ,14 2
7 M 68 Descending colon 11 Tubular High + + 2 ,14 2
8 1 F 74 Caecum 13 Villous Low + + 2
2 Transverse colon 38 Villous Low + + 2
3 Transverse colon 12 Tubular Low + + 2
4 Transverse colon 8 Villous Low + + 2
5 Sigmoid colon 17 Villous Low + + +
9 1 M 68 Sigmoid colon 10 Tubular Low + + + ,14 2
2 Sigmoid colon 11 Villous Low + + +
10 1 F 63 Ascending colon 4 Villous Low + 2 2 50 2
2 Descending colon 11 Tubular Low + + 2
3 Sigmoid colon 14 Tubular Low + + +
11 M 73 Sigmoid colon 11 Tubular Low + + + ,14 2
12 1 M 66 Ascending colon 11 Tubular Low + + 2 ,14 2
2 Rectum 15 Tubular Low + + +
3 Rectum 12 Villous Low + + +
13 M 64 Sigmoid colon 16 Villous Low + 2 +
14 M 57 Sigmoid colon 22 Villous High + + + 96 +
15 1 F 56 Sigmoid colon 13 Tubular Low + + + 132 2
2 Sigmoid colon 7 Tubular High + + +
16 M 56 Rectum 15 Villous Low + + + ,14 2
17 M 70 Transverse colon 57 Carcinoma Low + + 2 .765 +
18 M 61 Transverse colon 18 Tubular Low + + 2
19 F 58 Sigmoid colon 13 Tubular Low + + + ,14 2
20 1 M 53 Sigmoid colon 11 Villous Low + + +
2 Sigmoid colon 14 Villous Low + + +
21 M 55 Caecum 12 Tubular Low + + 2 ,14 2
22 M 69 Rectum 13 Tubular Low + + + .765 2
23 F 69 Sigmoid colon 12 Tubular Low + + + ,14 2
24 M 51 Descending colon 13 Tubular Low + + 2 ,14 +
25 F 63 Descending colon 10 Serrated Low + 2 2 ,14 2
26 M 67 Descending colon 8 Villous Low + + 2 2
27 1 F 64 Descending colon 5 Tubular High + + 2 248 2
2 Rectum 8 Villous Low + + +
3 Sigmoid colon 4 Villous Low + + +
28 F 69 Sigmoid colon 5 Villous Low + + + ,14 2
29 F 70 Sigmoid colon 5 Serrated Low + + + ,14 2
30 M 55 Sigmoid colon 8 Villous Low + + + ,14 2
CTC, CT colonography; FIT, faecal immunochemical stool testing; FOBT, faecal occult blood testing; FS, flexible sigmoidoscopy; OC optical colonoscopy.
Colonic cancer
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in fig 1. In contrast, sigmoidoscopy, FIT and FOBT only
identified 68, 33.3 and 23.8% of patients with adenomas
>10 mm. All tests except sigmoidoscopy identified a stage T3
colorectal cancer in the transverse colon of a 72-year-old man.
Combination of sigmoidoscopy with FOBT or FIT resulted in
increased detection rates for large adenomas of 76.2% and
71.4%, respectively, compared with FS alone (68%). A total of
269 patients had both stool tests, while only one of the tests
was available in 38 patients; analysis of the group of 269
patients who had all tests did not differ significantly from the
analysis including all 307 patients.
We detected 147 adenomas (5 mm and 41 adenomas 6–9 mm
in size. Thirteen of these small adenomas were of advanced
histology. The other 33 (72%) advanced adenomas were>10 mm
in size. OC identified 100% and CTC 96.7% of patients with
advanced colonic neoplasia. The specificities of both methods
equalled each other and resulted in similar positive and negative
predictive values (table 3). The sensitivity according to the patient
of sigmoidoscopy was higher for advanced lesions (25/30 patients,
83.3%) than for adenoma >10 mm (17/25 patients, 68.0%),
reflecting the higher likelihood of advanced lesions in the
rectosigmoid (27 of 46) compared with the rest of the colon (19
of 46). The sensitivities of FOBT and FIT for advanced lesions and
adenoma >10 mm were not significantly different. Therefore,
combination of sigmoidoscopy with stool tests did not increase
sensitivity for advanced colonic neoplasia.
An analysis according to the polyp was performed for
colonoscopy and CTC (table 4). The sensitivities for adenomas
of all sizes was much higher for colonoscopy, with 212 of 221
(95.9%) lesions detected compared with 155 adenomas (70.1%)
detected by CTC. This is mainly due to the comparably low
performance of CTC in the diminutive size group. CTC only
detected 59.2% of diminutive but 90.2% of 6–9 mm adenomas
compared with colonoscopy, which detected 94.6% and 92.7%.
In contrast, CTC detected 31 of 33 (93.9%) lesions in the large
adenoma group and 43 of 46 (93.5%) lesions in the advanced
colonic neoplasia group. This was comparable with the
detection rates of colonoscopy with sensitivities of 100% and
97.8%, respectively, in the two categories. CTC had a higher
sensitivity for small adenomas with advanced histology. While
sensitivity of CTC for adenomas ,10 mm was only 66%, CTC
missed only one adenoma of those with advanced histology in
this size group, resulting in a sensitivity of 93.5% for advanced
colonic neoplasia of all sizes, which equals the sensitivity of
colonoscopy.
In addition to identifying all patients with advanced colonic
neoplasia an ideal colorectal cancer screening test would also be
negative in all unaffected individuals. CTC had a per-patient
specificity for polyps >6 mm of 93.1% and a specificity for
patients without a polyp >10 mm of 97.9%. The specificity of
FOBT and FIT was 89.8% and 88.2%, respectively.
A total of 256 patients (83.4%) returned questionnaires for
analysis, and 114 of these had sedation for OC. Regarding
patient comfort, there was no difference between CTC and OC:
214 (83.6%) patients rated discomfort at CTC as ‘‘absent’’,
‘‘very mild’’ or ‘‘mild’’, and 210 (82.0)% chose these categories
for OC. Thirty-seven per cent preferred OC for future screening,
46% CTC (p,0.001), and 17% had no preference.
Table 3 Performance characteristics of OC, CTC, FS, FOBT and FIT in the detection of colonic adenomas in asymptomatic adults.
All sizes .5 mm .9 mm Advanced colonic neoplasia
No./total no. (% (95% CI)) No./total no. (% (95% CI)) No./total no. (% (95% CI)) No./total no. (% (95% CI))
OC Sens 110/113 (97.3 (92.4 to 99.4)) 45/46 (97.8 (88.5 to 99.9)) 25/25 (100.0 (86.3 to 100.0)) 30/30 (100 (88.4 to 100))
Spec 116/194 (59.8 (52.5 to 66.8)) 250/261 (95.8 (92.6 to 97.9)) 278/282 (98.6 (96.4 to 99.6)) 119/277 (43.0 (37.1 to 49))
PPV 110/188 (58.5 (51.1 to 65.6)) 45/56 (80.4 (67.6 to 89.8)) 25/29 (86.2 (68.3 to 96.1)) 30/188 (16.0 (11.0 to 22.0))
NPV 116/119 (97.5 (92.8 to 99.5)) 250/251 (99.6 (97.8 to 100)) 278/278 (100.0 (98.7 to 100.0)) 119/119 (100 (96.9 to 100))
FS Sens 81/113 (71.7 (62.4 to 79.8)) 31/46 (67.4 (52.0 to 80.5)) 17/25 (68.0 (46.5 to 85.1)) 25/30 (83.3 (65.3 to 94.4))
Spec 138/194 (71.1 (64.2 to 77.4)) 258/261 (98.9 (96.7 to 99.8)) 281/282 (99.6 (98.0 to 100.0)) 165/277 (59.6(53.5 to 65.4))
PPV 81/137 (59.1 (50.4 to 67.4)) 31/34 (91.2 (76.3 to 98.1)) 17/18 (94.4 (72.7 to 99.9)) 25/137 (18.2(12.2 to 25.7))
NPV 138/170 (81.2 (74.5 to 86.8)) 258/273 (94.5 (91.1 to 96.9)) 281/289 (97.2 (94.6 to 98.8)) 165/170 (97.1(93.3 to 99))
CTC Sens 95/113 (84.1 (76.0 to 90.3)) 42/46 (91.3 (79.2 to 97.6)) 23/25 (92.0 (74.0 to 99.0)) 29/30 (96.7(82.8 to 99.9))
Spec 92/194 (47.4 (40.2 to 54.7)) 243/261 (93.1 (89.3 to 95.9)) 276/282 (97.9 (95.4 to 99.2)) 109/277 (39.4 (33.6 to 45.4))
PPV 95/197 (48.2 (41.1 to 55.4)) 42/60 (70.0 (56.8 to 81.2)) 23/29 (79.3 (60.3 to 92.0)) 29/197 (14.7(10.1 to 20.5))
NPV 92/110 (83.6 (75.4 to 90.0)) 243/247 (98.4 (95.9 to 99.6)) 276/278 (99.3 (97.4 to 99.0)) 109/110 (99.1(95.0 to 100))
FOBT Sens 20/99 (20.2 (12.8 to 29.5)) 7/40 (17.5 (7.3 to 32.8)) 5/21 (23.8 (8.2 to 47.2)) 5/25 (20.0 (6.8 to 40.7))
Spec 166/177 (93.8 (89.2 to 96.9)) 212/236 (89.8 (85.2 to 93.4)) 229/255 (89.8 (85.4 to 93.2)) 225/251 (89.6 (85.2 to 93.1))
PPV 20/31 (64.5 (45.4 to 80.8)) 7/31 (22.6 (9.6 to 41.1)) 5/31 (16.1 (5.5 to 33.7)) 5/31 (16.1 (5.5 to 33.7))
NPV 166/245 (67.8 (61.5 to 73.6)) 212/245 (86.5 (81.6 to 90.5)) 229/245 (93.5 (89.6 to 96.2)) 225/245 (91.8 (87.7 to 94.9))
FIT Sens 25/102 (24.5 (16.5 to 34.0)) 16/40 (40.0 (24.9 to 56.7)) 7/21 (33.3 (14.6 to 57.0)) 8/25 (32.0 (14.9 to 53.5))
Spec 163/183 (89.1 (83.6 to 93.2)) 216/245 (88.2 (83.4 to 91.9)) 226/264 (85.6 (80.8 to 89.6)) 223/260 (85.8 (80.9 to 89.8))
PPV 25/45 (55.6 (40.0 to 70.4)) 16/45 (35.6 (21.9 to 51.2)) 7/45 (15.6 (6.5 to 29.5)) 8/45 (17.8 (8.0 to 32.1))
NPV 163/240 (67.9 (61.6 to 73.8)) 216/240 (90.0 (85.5 to 93.5)) 226/240 (94.2 (90.4 to 96.8)) 223/240 (92.9 (88.9 to 95.8))
FS + FOBT Sens 71/99 (71.7 (61.8 to 80.3)) 28/40 (70.0 (53.5 to 83.4)) 16/21 (76.2 (52.8 to 91.8)) 20/25 (80.0 (59.3 to 93.2))
Spec 120/177 (67.8 (60.4 to 74.6)) 211/236 (89.4 (84.8 to 93.0)) 228/255 (89.4 (85.0 to 92.9)) 143/251 (57.0 (50.6 to 63.2))
PPV 71/128 (55.5 (46.4 to 64.3)) 28/53 (52.8 (38.6 to 66.7)) 16/43 (37.2 (23.0 to 53.3)) 20/128 (15.6 (9.8 to 23.1))
NPV 120/148 (81.1 (73.8 to 87.0)) 211/223 (94.6 (90.8 to 97.2)) 228/233 (97.9 (95.1 to 99.3)) 143/148 (96.6 (92.3 to 98.9))
FS + FIT Sens 79/102 (77.5 (68.1 to 85.1)) 32/40 (80.0 (64.4 to 90.9)) 15/21 (71.4 (47.8 to 88.7)) 21/25 (84.0(63.9 to 95.5))
Spec 119/183 (65.0 (57.6 to 71.9)) 215/245 (87.8 (83.0 to 91.6)) 225/264 (85.2 (80.4 to 89.3)) 138/260 (53.1 (46.8 to 59.3))
PPV 79/143 (55.2 (46.7 to 63.6)) 32/62 (51.6 (38.6 to 64.5)) 15/54 (27.8(16.5 to 41.6)) 21/143 (14.7 (9.3 to 21.6))
NPV 119/142 (83.8 (76.7 to 89.4)) 215/223 (96.4 (93.1 to 98.4)) 225/231 (97.4(94.4 to 99.0)) 138/142 (97.2 (92.9 to 99.2))
Analysis according to the patient.
CTC, CT colonography; FIT, faecal immunochemical stool testing; FOBT, faecal occult blood testing; FS, flexible sigmoidoscopy; NPV, negative predictive value; OC optical
colonoscopy; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.
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DISCUSSION
Colorectal cancer is believed to be largely preventable through
effective screening.2 However, compliance with current screen-
ing recommendations is low and several predictors of non-
adherence to screening colonoscopy have been identified.31–33 A
major deterrent from screening is non-compliance with colono-
scopy. Therefore, alternative strategies, including self-propelling
and self-navigating colonoscopes, capsule colonoscopy, virtual
colonography based on CT or MRI, and new generation stool
tests based on immunological detection of blood or detection of
DNA mutations, have been proposed and are at different stages
of development.8 34 Prior to introduction, these methods need to
be prospectively evaluated and compared with established tests.
There is good evidence that screening of asymptomatic
persons with the use of FOBT or sigmoidoscopy can reduce
mortality from colorectal cancer.23 35 36 Several studies have
analysed the combination of sigmoidoscopy with FOBT and
found that combining the tests resulted in increased sensitivity
for advanced neoplasia.2 4 37 In our study, we deduced FS results
from colonoscopy by determining the rectum and sigmoid colon
as being accessible for this test. Population sensitivity of
sigmoidoscopy for advanced adenoma was 83.3%, which is in
accordance with the above-mentioned studies. Our results for
FS might have been improved by rigorous bowel preparation,
which normally would not be employed for sigmoidoscopy.
FOBT only detected 20% of advanced adenomas, and combina-
tion of FS with FOBT only resulted in an increase in the
detection rate of large adenomas but not advanced adenomas.
Immunochemical-based FITs detect human Hb in stool and
have higher sensitivities for advanced colonic neoplasia than
guaiac-based FOBT.14 38 We found that FIT identified 32% of
patients with advanced and 33.3% of patients with large
adenomas, and the combination of FIT with FS resulted in only
a slight increase in detection rates.
CTC is currently the most promising new screening method,
and several studies have reported high sensitivities for adeno-
mas.8 13 Additionally, CTC has now for the first time been
recommended for colorectal cancer screening by the American
Cancer Society.39 We used a 64-multidetector row CTC scanner
that provides 0.4 mm isotropic resolution and employed 3D
endoluminal CTC interpretation using a dedicated workstation.
Reconstructing 0.75 mm slices leads to higher spatial resolution
than in other trials published to date. This may have
contributed to the high sensitivities for adenomas in our study.
Interestingly, our CTC approach detected the majority of
advanced adenomas ,10 mm in diameter. This may have been
caused by the small number of advanced lesions in this size
group; however, it has been postulated that adenomas in
general are less deformable than non-neoplastic lesions, which
leads to increased conspicuity at CTC.40 41
The relevance of diminutive and small polyps 1–9 mm in size
has recently become a controversial topic.42 At least 20–30% of
the average risk asymptomatic population above age 50 carry
adenomatous polyps.43 The majority of these are ,10 mm.
However, controversy exists as to the likelihood that small
adenomas harbour significant advanced histology or progress to
colorectal cancer. This has important implications for reporting
and follow-up. A recent consensus proposal for CTC reporting
suggested that diminutive polyps do not need to be reported,
and patients with (2 polyps of ,10 mm are recommended to
undergo follow-up CTC after 3 years rather than immediate
colonoscopy for polypectomy, which is recommended for large
polyps or if >3 small polyps are present.26 As small and medium
size lesions may contain advanced histology,42 following this
Figure 1 (A) High-resolution 3D CT colonography endoluminal view
shows a 2.2 cm sessile polyp (marker ‘‘22a’’) in the ascending colon in a
72-year-old asymptomatic female. (B) Corresponding coronally
reformatted CT image showing the same lesion. Isotropic data sets allow
for reformation of images in any desired plane. (C) At colonoscopy, the
lesion is confirmed. Histopathology revealed villous adenoma.
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recommendation might lead to an increase in colorectal cancer
incidence and mortality.25
Another important issue is radiation exposure during CTC.
Standard CTC techniques apply up to 12 mSv.12 15 44 It has been
estimated that any amount of ionising radiation may lead to an
increase in radiation-related cancer and death, and that up to
2% of cancers in the USA may be induced by diagnostic CT
examinations.12 19 Therefore, medical imaging-associated radia-
tion needs to be kept to a minimum especially in screening
procedures. Using low-dose protocols and new dose modulation
techniques, we were able to decrease the mean radiation dose to
4.5 mSv for the entire examination. This value is significantly
lower than the dose values reported in or calculated from other
major trials that used spatial resolutions inferior to our protocol,
and is lower than measured values for a 64-detector system
without dose modulation techniques.45 Remarkably, image
quality remained high even in the pelvis, an anatomical region
that is prone to image noise-induced artefacts in CTC.22 45
Although more patients preferred CTC than OC for future
screening (46% vs 37%), this preference was not as clear as in
other comparative trials. Preferences were dependent on use of
sedation for OC.
In conclusion, our results show that CTC performs equally as
well as colonoscopy in detecting advanced adenomas. Therefore,
future screening guidelines might include CTC as a primary
screening test as an alternative to colonoscopy. Prerequisites for
colorectal cancer screening by CTC are adequate training of
radiologists, employment of high-resolution low-dose CT
technique, and opportunity of same-day colonoscopy in the
case of relevant findings in order to avoid repeat bowel
preparation. FS should be preferred to stool tests in patients
who refuse to undergo full bowel preparation or total
colonoscopy. FIT has a higher sensitivity for adenomas than
FOBT, but both stool tests are inferior to tests that allow
visualisation of the colonic mucosa.
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